|Symptoms||Acne, tender breasts, bloating, feeling tired, mood changes|
|Complications||Premenstrual dysphoric disorder|
|Usual onset||1–2 weeks before menstruation|
|Risk factors||High-salt diet, alcohol, caffeine|
|Diagnostic method||Based on symptoms|
|Treatment||Lifestyle changes, medication|
|Medication||Calcium and vitamin D supplementation, NSAIDs, birth control pills|
|Frequency||~25% of menstruating women|
Premenstrual syndrome (PMS) refers to emotional and physical symptoms that regularly occur in the one to two weeks before a woman's period. Symptoms often vary between women and resolve around the start of bleeding. The common emotional symptoms include irritability and mood changes while the common physical symptoms include acne, tender breasts, bloating, and feeling tired; these are also seen in women without PMS. Often symptoms are present for around six days. A woman's pattern of symptoms may change over time. Symptoms do not occur during pregnancy or following menopause.
Diagnosis requires a consistent pattern of emotional and physical symptoms occurring after ovulation and before menstruation to a degree that interferes with normal life. Emotional symptoms must not be present during the initial part of the menstrual cycle. A daily list of symptoms over a few months may help in diagnosis. Other disorders that cause similar symptoms need to be excluded before a diagnosis is made.
The cause of PMS is unknown. Some symptoms may be worsened by a high-salt diet, alcohol, or caffeine. The underlying mechanism is believed to involve changes in hormone levels. Reducing salt, caffeine, and stress along with increasing exercise is typically all that is recommended in those with mild symptoms. Calcium and vitamin D supplementation may be useful in some. Anti-inflammatory drugs such as naproxen may help with physical symptoms. In those with more significant symptoms birth control pills or the diuretic spironolactone may be useful.
Up to 80% of women report having some symptoms prior to menstruation. These symptoms qualify as PMS in 20 to 30% of pre-menopausal women. Premenstrual dysphoric disorder (PMDD) is a more severe form of PMS that has greater psychological symptoms. PMDD affects three to eight percent of pre-menopausal women. Antidepressant medication of the selective serotonin reuptake inhibitors class may be used for PMDD in addition to the usual measures for PMS.
Signs and symptoms
More than 200 different symptoms have been associated with PMS. Common emotional and non-specific symptoms include stress, anxiety, difficulty with sleep, headache, feeling tired, mood swings, increased emotional sensitivity, and changes in interest in sex.
Physical symptoms associated with the menstrual cycle include bloating, lower back pain, abdominal cramps, constipation/diarrhea, swelling or tenderness in the breasts, cyclic acne, joint or muscle pain, and food cravings. The exact symptoms and their intensity vary significantly from woman to woman, and even somewhat from cycle to cycle and over time. Most women with premenstrual syndrome experience only a few of the possible symptoms, in a relatively predictable pattern.
While PMS is linked to the luteal phase, the causes of PMS are not clear, but several factors may be involved. Changes in hormones during the menstrual cycle seem to be an important factor; changing hormone levels affect some women more than others. However, some authors say that, after the death of the corpus luteum, the loss of progesterone, a central nervous system depressant, is the base of the PMS. Chemical changes in the brain, stress, and emotional problems, such as depression, do not seem to cause PMS but they may make it worse. Low levels of vitamins and minerals, high sodium, alcohol, and/or caffeine can exacerbate symptoms such as water retention and bloating. PMS occurs more often in women who are between their late 20s and early 40s; have at least 1 child; have a family history of depression; and have a past medical history of either postpartum depression or a mood disorder.
There are no laboratory tests or unique physical findings to verify the diagnosis of PMS. The three key features are:
- The woman's chief complaint is one or more of the emotional symptoms associated with PMS (most typically irritability, tension, or unhappiness).
- Symptoms appear predictably during the luteal (premenstrual) phase, reduce or disappear predictably shortly before or during menstruation, and remain absent during the follicular (preovulatory) phase.
- The symptoms must be severe enough to interfere with the woman's everyday life.
Mild PMS is common, and more severe symptoms would qualify as PMDD. PMS is not listed in the DSM-IV, unlike PMDD. To establish a pattern and determine if it is PMDD, a woman's physician may ask her to keep a prospective record of her symptoms on a calendar for at least two menstrual cycles. This will help to establish if the symptoms are, indeed, limited to the premenstrual time, predictably recurring, and disruptive to normal functioning. A number of standardized instruments have been developed to describe PMS, including the Calendar of Premenstrual syndrome Experiences (COPE), the Prospective Record of the Impact and Severity of Menstruation (PRISM), and the Visual Analogue Scales (VAS).
Other conditions that may better explain symptoms must be excluded. A number of medical conditions are subject to exacerbation at menstruation, a process called menstrual magnification. These conditions may lead the woman to believe that she has PMS, when the underlying disorder may be some other problem, such as anemia, hypothyroidism, eating disorders and substance abuse. A key feature is that these conditions may also be present outside of the luteal phase. Conditions that can be magnified perimenstrually include depression or other affective disorders, migraine, seizure disorders, fatigue, irritable bowel syndrome, asthma, and allergies. Problems with other aspects of the female reproductive system must be excluded, including dysmenorrhea (pain during the menstrual period, rather than before it), endometriosis, perimenopause, and adverse effects produced by oral contraceptive pills.
The National Institute of Mental Health research definition compares the intensity of symptoms from cycle days 5 to 10 to the six-day interval before the onset of the menstrual period. To qualify as PMS, symptom intensity must increase at least 30% in the six days before menstruation. Additionally, this pattern must be documented for at least two consecutive cycles.
Many treatments have been tried in PMS. Reducing salt, caffeine, and stress along with increasing exercise is typically all that is recommended in those with mild symptoms. Calcium and vitamin D supplementation may be useful in some. Antiinflammatories such as naproxen may help with physical symptoms. In those with more significant symptoms birth control pills may be useful.
SSRIs like fluoxetine, sertraline can be used to treat severe PMS. Women with PMS may be able to take medication only on the days when symptoms are expected to occur. Although intermittent therapy might be more acceptable to some women, this might be less effective than continuous regimens. Side effect such as nausea and weakness are however relatively common.
Hormonal contraception is commonly used; common forms include the combined oral contraceptive pill and the contraceptive patch. This class of medication may cause PMS-related symptoms in some women, and may reduce physical symptoms in others. They do not relieve emotional symptoms.
Gonadotropin-releasing hormone agonists can be useful in severe forms of PMS but have their own set of significant potential side effects.
PMS is generally a stable diagnosis, with susceptible women experiencing the same symptoms at the same intensity near the end of each cycle for years. Treatment for specific symptoms is usually effective.
Even without treatment, symptoms tend to decrease in perimenopausal women. However, women who experience PMS or PMDD are more likely to have significant symptoms associated with menopause, such as hot flashes.
Up to 80% of women of child-bearing age report having some symptoms prior to menstruation. These symptoms qualify as PMS in 20 to 30% of women and in three to eight percent are severe.
PMS was originally seen as an imagined disease. Women who reported its symptoms were often told it was "all in their head". Woman’s reproductive organs were thought to have complete control over them. Women were warned not to divert needed energy away from the uterus and ovaries. This view of limited energy very quickly ran up against a reality in 19th century America that young girls worked extremely long and hard hours in factories; newspapers in the 19th century were peppered with remedies to help in the "tyrannous processes" of the menstrual cycle. In 1873 Edward Clarke published an influential book titled Sex in Education. Clarke came to a conclusion that female operatives suffer less than schoolgirls because they "work their brain less". This suggested that they have stronger bodies and a reproductive "apparatus more normally constructed". Feminists later took opposition to Clarke's argument that women should not leave the private sphere by showing how woman could function in the world outside the home in spite of their bodily functions.
The formal medical description of premenstrual syndrome (PMS) and the more severe, related diagnosis of premenstrual dysphoric disorder (PMDD) goes back at least 70 years to a paper presented at the New York Academy of Medicine by Robert T. Frank titled "Hormonal Causes of Premenstrual Tension". The specific term premenstrual syndrome appears to date from an article published in 1953 by Dalton and Greene in the British Medical Journal. Since then, PMS has been a continuous presence in popular culture, occupying a place that is larger than the research attention accorded it as a medical diagnosis. It has been argued that women are partially responsible for the medicalization of PMS. By legitimizing this disorder, women have contributed to the social construction of PMS as an illness. It has also been suggested that the public debate over PMS and PMDD was impacted by organizations who had a stake in the outcome including feminists, the American Psychiatric Association, physicians and scientists. Until the 1950s, there was little research done surrounding PMS and it was not seen as a social problem. By the 1980s, however, viewing PMS in a social context had begun to take place.
Some supporters of PMS as a social construct believe PMDD and PMS to be unrelated issues: according to them, PMDD is a product of brain chemistry, and PMS is a product of a hypochondriatic culture, i.e. a culture-bound syndrome. Most studies on PMS and PMDD rely solely on self-reporting. According to sociologist Carol Tavris, Western women are socially conditioned to expect PMS or to at least know of its existence, and they therefore report their symptoms accordingly. The anthropologist Emily Martin argues that PMS is a cultural phenomenon that continues to grow in a positive feedback loop, and thus is a social construction that contributes to learned helplessness or convenient excuse. Tavris says that PMS is blamed as an explanation for rage or sadness. The decision to call PMDD an illness has been criticized as inappropriate medicalization. In both cases, they are referring to the emotional aspects, not the normal physical symptoms that are present.
- "Premenstrual syndrome (PMS) fact sheet". Office on Women's Health. December 23, 2014. Archived from the original on 28 June 2015. Retrieved 23 June 2015. CS1 maint: discouraged parameter (link)
- Biggs, WS; Demuth, RH (15 October 2011). "Premenstrual syndrome and premenstrual dysphoric disorder". American Family Physician. 84 (8): 918–24. PMID 22010771.
- Dickerson, Lori M.; Mazyck, Pamela J.; Hunter, Melissa H. (2003). "Premenstrual Syndrome". American Family Physician. 67 (8): 1743–52. PMID 12725453. Archived from the original on 2008-05-13. CS1 maint: discouraged parameter (link)
- "Merck Manual Professional - Menstrual Abnormalities". November 2005. Archived from the original on 2007-02-12. Retrieved 2007-02-02. CS1 maint: discouraged parameter (link)
- Johnson S, PHD. "Premenstrual Syndrome (Premenstrual Tension)". Menstrual Abnormalities and Abnormal Uterine Bleeding. Armenian Health Network, Health.am. Archived from the original on 2009-02-09. Retrieved 2008-01-10. CS1 maint: discouraged parameter (link)
- "MayoClinic.com: Premenstrual syndrome (PMS): Signs and symptoms". MayoClinic.com. 2006-10-27. Archived from the original on 2007-01-25. Retrieved 2007-02-02. CS1 maint: discouraged parameter (link)
- Rapkin, Andrea J; Lewis, Erin I (2013). "Treatment of Premenstrual Dysphoric Disorder". Women's Health. 9 (6): 537–56. doi:10.2217/whe.13.62. PMID 24161307.
- Koeppen, Bruce M.; Stanton, Bruce A (2008). Berne & Levy physiology (6th ed.). Elsevier. p. 790. ISBN 978-85-352-3057-4.
- Marjoribanks J, Brown J, O'Brien PM, Wyatt K; Brown; O'Brien; Wyatt (Jun 7, 2013). "Selective serotonin reuptake inhibitors for premenstrual syndrome" (PDF). The Cochrane Database of Systematic Reviews (6): CD001396. doi:10.1002/14651858.CD001396.pub3. PMC 7073417. PMID 23744611.CS1 maint: multiple names: authors list (link)
- "Low Doses Of Anti-depressant May Help Some Women Suffering From Moderate-to-severe PMS". Sciencedaily.com. 2006-10-14. Archived from the original on 2012-10-21. Retrieved 2012-12-25. CS1 maint: discouraged parameter (link)
- Shah, Nirav R.; Jones, J B.; Aperi, Jaclyn; Shemtov, Rachel; Karne, Anita; Borenstein, Jeff (2008). "Selective Serotonin Reuptake Inhibitors for Premenstrual Syndrome and Premenstrual Dysphoric Disorder". Obstetrics & Gynecology. 111 (5): 1175–82. doi:10.1097/AOG.0b013e31816fd73b. PMC 2670364. PMID 18448752.
- Ford, O; Lethaby, A; Roberts, H; Mol, BW (14 March 2012). "Progesterone for premenstrual syndrome". The Cochrane Database of Systematic Reviews (3): CD003415. doi:10.1002/14651858.CD003415.pub4. PMC 7154383. PMID 22419287.
- Armour, M; Ee, CC; Hao, J; Wilson, TM; Yao, SS; Smith, CA (14 August 2018). "Acupuncture and acupressure for premenstrual syndrome". The Cochrane Database of Systematic Reviews. 8: CD005290. doi:10.1002/14651858.CD005290.pub2. PMC 6513602. PMID 30105749.
- Roca, CA; Schmidt, PJ; Rubinow, DR (1999). "A follow-up study of premenstrual syndrome". The Journal of Clinical Psychiatry. 60 (11): 763–6. doi:10.4088/JCP.v60n1108. PMID 10584765.
- "LifeWatch - Women's Health - Women's Reproductive Health: PMS". Archived from the original on 2009-02-10. Retrieved 2008-01-13. CS1 maint: discouraged parameter (link)
- Lane, Darina (2011-07-20). "The Curse of PMS" (PDF). Evening Echo. Thomas Crosbie Holdings. p. 11. Archived from the original (PDF) on 2013-12-05. Retrieved 2012-06-03. CS1 maint: discouraged parameter (link)
- Greene, Raymond and Katharina D. Dalton. (1953). "The Premenstrual Syndrome". British Medical Journal. 1 (4818): 1007–14. doi:10.1136/bmj.1.4818.1007. PMC 2016383. PMID 13032605.
- Markens, Susan (1996). "The Problematic of 'Experience': A Political and Cultural Critique of PMS". Gender & Society. 10 (1): 42–58. doi:10.1177/089124396010001004. JSTOR 189552.
- Figert, Anne E. (1995). "The Three Faces of PMS: The Professional, Gendered, and Scientific Structuring of a Psychiatric Disorder". Social Problems. 42 (1): 56–73. doi:10.1525/sp.1995.42.1.03x0455m. JSTOR 3097005.
- Carol Tavris, The Mismeasure of Woman (New York: Simon & Schuster, 1992), 144.
- Carol Tavris, The Mismeasure of Woman (New York: Simon & Schuster, 1992), 142.
- Does PMDD Belong in the DSM? Challenging the Medicalization of Women's Bodies Archived 2011-06-28 at the Wayback Machine Journal article by Alia Offman, Peggy J. Kleinplatz; The Canadian Journal of Human Sexuality, Vol. 13, 2004
- U.S. Department of Health & Human Services
- Direct Online Health Encyclopaedia: Premenstrual syndrome (UK) at NHS
- "Premenstrual Syndrome (PMS) (Premenstrual Tension)" at Merck Manual
Lua error in Module:Authority_control at line 1096: attempt to index field 'wikibase' (a nil value).